In total, over the past three years, we have absorbed around DKK 450 million in extraordinary costs for component and logistics.

Source: https://www.marketscreener.com/quote/stock/BANG-OLUFSEN-A-S-1412850/news/Bang-Olufsen-a-s-Chairman-s-speech-44711190/?utm_medium=RSS&utm_content=20230828

Looking at the "Diabetes and Obesity Care" segment in more detail, growth was especially driven by GLP-1 sales, which increased from DKK 53,597 million in the previous year to DKK 83,371 million in fiscal 2022.

Source: https://seekingalpha.com/article/4593840-novo-nordisk-stock-good-business-model-high-valuation-multiples-reiterate-hold?source=feed_all_articles

Looking at the "Diabetes and Obesity Care" segment in more detail, growth was especially driven by GLP-1 sales, which increased from DKK 53,597 million in the previous year to DKK 83,371 million in fiscal 2022.

Source: https://seekingalpha.com/article/4593840-novo-nordisk-stock-good-business-model-high-valuation-multiples-reiterate-hold?source=feed_all_articles

The average daily volume in Copenhagen is 15,000 shares per day representing a monetary value of 3.3M DKK per day.

Source: https://seekingalpha.com/article/4660216-sp-group-anticipate-further-ebitda-growth-after-a-transition-year?source=feed_all_articles

Under the programme initiated 9 May 2023, Novo Nordisk will repurchase B shares for an amount up to DKK 5.8 billion in the period from 10 May 2023 to 8 August 2023.

Source: https://www.marketscreener.com/quote/stock/NOVO-NORDISK-A-S-1412980/news/Novo-Nordisk-A-S-share-repurchase-programme-44140926/?utm_medium=RSS&utm_content=20230619

Zealand has approximately DKK 162.6 million in cash deposits held at SVB as of March 10, 2023, which represents approximately 15% of its total cash, cash equivalents and marketable securities on that date.

Source: https://www.marketscreener.com/quote/stock/ZEALAND-PHARMA-A-S-6970764/news/Zealand-Pharma-Provides-Statement-on-Silicon-Valley-Bank-Closure-43220937/?utm_medium=RSS&utm_content=20230312